Adverse events · people requiring treatment for acute DVT
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes adverse events compared with BMP alone (very low certainty).
1 finding from 1 review
Adverse events · people requiring treatment for chronic DVT
1 finding from 1 review
Adverse events · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in adverse events compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (not reported) · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in adverse events (not reported) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
GRADE not reported
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Intervention not reported
Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found